Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia

Abstract

Aim: Objective was to compare adherence and persistence, as well as direct healthcare costs and utilization, of ospemifene to available local estrogen therapies (LETs). Patients & methods: This retrospective database study used integrated medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims – US Database. Results: Ospemifene patients had significantly greater adherence and persistence compared with the other nonring LETs. Ospemifene had the lowest mean outpatient costs of any of the LET cohorts, including the estradiol vaginal ring. Total all-cause healthcare costs were also significantly less for ospemifene patients compared with all other LETs.

Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world

“…Following screening, 151 publications describing 123 studies with 34,740 ring users and 5,694 hypothetical users were included. Twenty-five studies were excluded from meta-analysis due to reporting product continuation without also reporting general acceptability [10,[28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47], reporting continuous rather than labelled categorical or dichotomous outcomes [48] and reporting preference data only [49,50] (Figure 1). Some secondary manuscripts of the included studies assessed acceptability across ring groups with different characteristics (e.g.…”

“…The studies included 51 countries, with 28 studies from Europe [ 33 , 34 , 37 , 39 , 40 , 43 , 49 – 71 ], 47 from North and South America and Australia [ 29 – 32 , 36 , 38 , 42 , 47 , 48 , 72 – 113 ], 18 from the Asia-Pacific [ 35 , 114 – 129 ], 17 from North and sub-Saharan Africa [ 10 , 28 , 44 , 46 , 130 – 143 ], and 13 from multiple regions [ 41 , 45 , 144 – 154 ]. Sixty-three studies evaluated rings used for contraception, 21 for menopause, 21 for HIV prevention, and five for MPT; of the 123 studies, 58 were RCTs, 58 were observational studies, and 7 were pharmacokinetic studies.…”

<p>Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use</p>

“…The study was performed in 86,946 patients with more than one pharmacy claim for dyspareunia-related medication. 57 Highest adherence was observed for ospemifene in comparison to non-ring local hormonal therapy e.g. conjugated oestrogen cream, oestradiol vaginal insert, and oestradiol cream (40% vs 21%; p<0.0001).…”

Ospemifene (Osphena)

“…In the submitted BIA, the sponsor calculated annual treatment discontinuation rates for ospemifene and all comparator treatments based on a retrospective claims analysis by Faught et al 2019. 3 It found ospemifene had the lowest rate of discontinuation among non-ring treatments (77.1% for ospemifene versus 95.0%, 83.6%, 93.7%, and 56.4%, for conjugated estrogen cream, estradiol vaginal insert, estradiol cream, and estradiol ring, respectively).…”